Firms admit colluding to keep nortriptyline price up
The Pfizer (NYSE: PFE) subsidiary King Pharmaceuticals and Alissa Healthcare Research have admitted illegally sharing information relating to nortriptyline in order to keep UK prices of the generic drug high.
In June 2019, the UK’s Competition and Markets Authority issued a statement of objections provisionally finding that the two companies, along with the wholesaler Lexicon, had exchanged commercially sensitive information about prices, volumes and entry plans in order to keep prices up.
Nortriptyline is prescribed by the National Health Service (NHS) and used by thousands of patients every month to relieve the symptoms of depression. It was previously sold under brand names including Pamelor and Noritren. NHS spending on the drug peaked at £38 million ($47 million) in 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze